UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Remo Panaccione  ¹     James O. Lindsay  ^{2, 3}     Julian Panés  ⁴     Petar Svorcan  ^{5, 6}     Muhammad N. Rajabally  ⁷     M DOLORES MARTIN ARRANZ  ^{8, 9}     Francesca Bresso  ^{10, 11}     Ana Paula Machado De Lacerda  ¹²     Elena Dubcenco  ¹²     Sharanya Ford  ¹²     Samuel Anyanwu  ¹²     Tian Feng  ¹²     Geert R. D'Haens  ^13    
1 University of Calgary, Calgary, Canada
² Barts Health NHS Trust, London, United Kingdom
³ Queen Mary University of London, London, United Kingdom
⁴ Hospital Clínic Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain
⁵ Zvezdara University Medical Center, Belgrade, Serbia
⁶ University of Belgrade, Belgrade, Serbia
⁷ Mediclinic Constantiaberg, Cape Town, South Africa
⁸ La Paz University Hospital, Madrid, Spain
⁹ Universidad Autónoma de Madrid, Madrid, Spain
¹⁰ Karolinska Institutet, Solna, Sweden
¹¹ Karolinska University Hospital, Stockholm, Sweden
¹² AbbVie Inc., North Chicago, United States
¹³ Amsterdam University Medical Centers, Amsterdam, Netherlands

Topic
IBD

Session
Hit the road JAK: Part 2

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)